Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Investor Presentation (February 2024)
25 slides from Lumos Diagnostics's investor presentation, Feb 5, 2024
Slide 1: Lumos Diagnostics Holdings Limited Investor Presentation
For personal use only Lumos Diagnostics Holdings Limited Investor Presentation February 2024 lumosdiagnostics.com 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Company Overview
For personal use only Company Overview
Slide 4: Company snapshot
Company snapshot Experienced leadership • Led by Doug Ward (CEO) - industry veteran with over 30 years' in diagnostics • Experienced business/technical/commercial leaders also include Lumos is a developer and Barrie Lambert (CFO); Sacha Dopheide (CTO) & Paul Kase (SVP Commercial Ops) For personal us
Slide 5: Company snapshot
Company snapshot Issued capital Share Price & Volume For personal use only Shares 481.3m Options 85.0m Market capitalization (AUD) Share price A$0.079 Market value A$38.2m Cash (pro-forma – Jan 24) A$9.7m Enterprise value A$28.5m Substantial shareholders Board and management Perennial Value Manageme
Slide 6: Highly experienced leadership team
Highly experienced leadership team For personal use only Doug Ward Barrie Lambert Sasha Dopheide, PhD Paul Kase CEO & Managing Director Chief Financial Officer Chief Technology Officer SVP of Commercial Operations Doug Ward has more than 30 years of biotech Barrie Lambert has more than 20 years of S
Slide 7: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering For personal use only 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers
Slide 8: How we add value to partners
How we add value to partners We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market For personal use only Customer launch and support Manufacture Clinical studies Verification and validation of Conduct feasibility, require
Slide 9: Lumos' POC diagnostic test development engine
Lumos’ POC diagnostic test development engine We are one of the few companies in the POC space that provides these integrated services to partners For personal use only Product Design Develop Manufacture concepts (generated by Lumos or partners/customers) REVENUE Contract fees Revenue & margin Sales
Slide 10: Financials - summary
Financials - summary (US$ in thousands) REVENUE GROSS PROFIT COMMENTARY For personal use only $6,428 $6,000 $5,448 $4,000 $3,376 80% $5,202 $5,087 $2,571 $2,571 $2,596 • Q2 FY24 unaudited revenue of US$1.7m, $3,000 62% 60% up 55% from Q1 of $1.1m $4,000 49% 51% $2,000 40% 40% • Implemented significa
Slide 11: Product Update
For personal use only Product Update
Slide 12: FebriDx: Lumos' launches first-of-its-kind POC test
FebriDx: Lumos’ launches first-of-its-kind POC test FebriDx offers an aid for healthcare providers to improve patient care and antibiotic stewardship For personal use only • Antibiotics often prescribed for respiratory infections unnecessarily (ie. patient had no bacterial infection)1 • Can result i
Slide 13: FebriDx addresses a major need: antibiotic overprescription
FebriDx addresses a major need: antibiotic overprescription ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED HOW WE’RE DRIVING MARKET ADOPTION For personal use only Common cold Marketing and education Sinusitis • Microbial testing prior to prescribing antibiotics not currently routi
Slide 14: FebriDx - commenced US product sales
FebriDx - commenced US product sales Commenced marketing activities to initial key customers For personal use only • Agreements with 14 customers/distributors • Additional discussions with urgent care and relevant physician offices through Lumos’ US sales channel • Identified CPT codes (USD $29.55)
Slide 15: ViraDx – Lumos' POC test for key respiratory infections
ViraDx – Lumos’ POC test for key respiratory infections ViraDx highly relevant POC test for post-pandemic environment: For personal use only • SARS-CoV-2 pandemic increased consumer and healthcare POC testing • ViraDx is a 3-in-1 test for COVID-19/’flu A/’flu B • One of two tests available in market
Slide 16: Services Update
For personal use only Services Update
Slide 17: Strategic partnerships are a key pillar of Lumos' growth plan
Strategic partnerships are a key pillar of Lumos’ growth plan Lumos provides a compelling service offering for leading diagnostics companies For personal use only • Fully-integrated offering—from concept-to-clinic-to-commercial production • Proprietary reader platform—integrate POC testing with elec
Slide 18: Hologic - strategic partnership
Hologic - strategic partnership Hologic is a recognized global leader in women’s health based in Massachusetts, US For personal use only • NASDAQ: HOLX, Market Capitalization ~US$18 billion • FY2023 revenue of US$4.0 billion with net income of US$0.5 billion • Diagnostic products account for ~50% of
Slide 19: Hologic - new major development and IP agreements
Hologic - new major development and IP agreements* Focus on improving one of Hologic's leading on-market women's health products and adapting it for use on Lumos’ For personal use only proprietary reader platform. Collaboration Builds on work jointly conducted over last 12+ months These new contract
Slide 20: Fetal Fibronectin (fFN) background
Fetal Fibronectin (fFN) background A biomarker indicating a heightened risk of pre-term delivery when present in cervicovaginal secretions For personal use only fFN is the largest segment in the • Background pre-term diagnostic test kit market • fFN is protein found at the maternal-fetal interface.
Slide 21: Hologic - fFN product development overview
Hologic - fFN product development overview Current test: Rapid fFN TLiQ Next generation test concept (mock-up) For personal use only Benefits of the new technology • Latest state-of-the-art technology, with reader platform • Connectivity for improved digital patient record management • Developed and
Slide 22: Hologic – the opportunity ahead
Hologic – the opportunity ahead For personal use only Verification and validation Clinical study Manufacturing Second test development and IP 22
Slide 23: Looking ahead
For personal use only Looking ahead
Slide 24: Key strategic priorities
Key strategic priorities For personal use only Drive FebriDx and ViraDx sales in US market through expanded sales channels Expand current partnerships and establish new strategic agreements Hologic – deliver on development milestones over next 18-24 months Improve operating cash flow through revenue
Slide 25: lumosdiagnostics.com
For personal use only lumosdiagnostics.com 25
Lumos Diagnostics Holdings — Investor Presentation (February 2024) on 6ix